Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk
- PMID: 21300721
- PMCID: PMC3112019
- DOI: 10.1093/cvr/cvr044
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk
Abstract
Aims: The level of inhibition of the human Ether-à-go-go-related gene (hERG) channel is one of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de-Pointes (TdP) arrhythmias. While avoiding the use of drugs with maximum therapeutic concentrations within 30-fold of their hERG inhibitory concentration 50% (IC(50)) values has been suggested, there are drugs that are exceptions to this rule: hERG inhibitors that do not cause TdP, and drugs that can cause TdP but are not strong hERG inhibitors. In this study, we investigate whether a simulated evaluation of multi-channel effects could be used to improve this early prediction of TdP risk.
Methods and results: We collected multiple ion channel data (hERG, Na, L-type Ca) on 31 drugs associated with varied risks of TdP. To integrate the information on multi-channel block, we have performed simulations with a variety of mathematical models of cardiac cells (for rabbit, dog, and human ventricular myocyte models). Drug action is modelled using IC(50) values, and therapeutic drug concentrations to calculate the proportion of blocked channels and the channel conductances are modified accordingly. Various pacing protocols are simulated, and classification analysis is performed to evaluate the predictive power of the models for TdP risk. We find that simulation of action potential duration prolongation, at therapeutic concentrations, provides improved prediction of the TdP risk associated with a compound, above that provided by existing markers.
Conclusion: The suggested calculations improve the reliability of early cardiac safety assessments, beyond those based solely on a hERG block effect.
Figures





Comment in
-
Early prediction of proarrhythmic cardiotoxicity in the drug development process.Cardiovasc Res. 2011 Jul 1;91(1):7-8. doi: 10.1093/cvr/cvr130. Epub 2011 May 9. Cardiovasc Res. 2011. PMID: 21555404 No abstract available.
References
-
- Pratt CM, Al-Khalidi HR, Brum JM, Holroyde MJ, Schwartz PJ, Marcello SR, et al. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol. 2006;48:471–477. - PubMed
-
- Darpö B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Supp. 2001;3:K70.
-
- Justo D, Prokhorov V, Heller K, Zeltser D. Torsade de pointes induced by psychotropic drugs and the prevalence of its risk factors. Acta Psychiatr Scand. 2005;111:171–176. - PubMed
-
- Bisset AF, Arshad P, Morcos M, Sridharan B. Discontinuation of thioridazine. BMJ. 2002;325:967. - PubMed
-
- Henney JE. Withdrawal of troglitazone and cisapride. JAMA. 2000;283:2228. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Miscellaneous